hardman & Co

2nd February 2018



Market data	
EPIC/TKR	AGY
Price (p)	30.0
12m High (p)	39.5
12m Low (p)	23.0
Shares (m)	594.1
Mkt Cap (£m)	178.2
EV (£m)	159.4
Free Float*	37%
Market	AIM
	*As defined by AIM Rule 26

Description

AGY provides information to professionals related to prevention, diagnosis and treatment of allergic conditions with special focus on allergy vaccination. The emphasis is on treating the underlying cause and not just the symptoms.

Company information						
CEO	Manuel Llobet					
CFO	Nick Wykeman					
Chairman	nairman Peter Jensen					
+44 1903 845 820						
www.allerg	sytherapeutics.com					

Key shareholder	s
Directors	0.7%
Abbott Labs	40.5%
Southern Fox	21.4%
Odey	7.4%
Invesco	4.8%
Diary	
7 March	Interims
2Q'18	Ph.II PQ Grass trial
2H'18	Ph.III PQBirch trial

Analysts	
Martin Hall	020 7194 7632
<u>mh@h</u>	ardmanandco.com
Dorothea Hill	020 7194 7626
<u>dmh@h</u>	ardmanandco.com
Gregoire Pave	020 7194 7628
<u>gp@h</u>	ardmanandco.com

Allergy Therapeutics

Growth in a tough market


AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'Named Patient' basis. Trials designed to obtain regulatory approval for PQ approved as a biologic in both Europe and the US are well advanced. Meanwhile, although underlying sales growth was weaker than expected in 1H'18, this was on the back of an unusually shorter and lower pollen season in central Europe, suggesting that AGY has continued to make further market share gains.

- Strategy: AGY is a fully integrated pharmaceutical company focused on the treatment of allergies. There are three parts to its strategy: continued development of its European business via investment or opportunistic acquisitions; the US PQ opportunity; and further development of its pipeline.
- Trading update: In 1H'18, underlying sales grew 1.3% to £42.2m (£40.4m), which was about 10% below expectations, largely because of an unexpectedly weak pollen season. Timing of R&D spend, coupled with careful control of costs and working capital, generated a cash position of £25.8m (£27.8m).
- Pollen season: Reports show that the pollen season was very weak in 2017, particularly in AGY's key markets of central Europe, Germany, Austria and Switzerland. Therefore, there is reason to believe that the low sales growth in 1H'18 was still sufficient for AGY to make further market share gains.
- R&D spend: Clinical trials designed to get full regulatory approval of Pollinex Quattro (PQ) as a biologic continue apace. The Phase III PQ Birch trial is fully recruited, with results due to be released in 2H calendar 2018. The Phase II PQ grass trial is still recruiting. Timing of R&D spend does affect the cash position.
- Investment summary: AGY is going through an exciting period, with a clear vision, gaining market share from competitors, and leading the race to have its products fully approved and regulated as biologicals first in Europe, then in the US, where the regulators are demanding change. Read-out from the EU Phase III PQ Birch trial in 2018 will provide the next major value inflection point.


Financial summary and valuation								
Year-end June (£m)	2015	2016	2017	2018E	2019E	2020E		
Sales	43.23	48.51	64.14	68.0	77.0	86.5		
R&D investment	-3.12	-16.22	-9.30	-18.0	-16.0	-8.0		
Underlying EBIT	2.91	-12.34	-2.89	-9.7	-5.9	8.1		
Reported EBIT	1.41	-12.53	-2.60	-10.4	-6.6	7.4		
Underlying PBT	2.84	-12.45	-2.97	-9.8	-6.0	8.0		
Statutory PBT	0.65	-12.21	-2.67	-10.5	-6.7	7.3		
Underlying EPS (p)	0.48	-2.36	-0.59	-1.6	-1.0	1.3		
Statutory EPS (p)	0.02	-2.29	-0.42	-1.7	-1.1	1.2		
Net (debt)/cash	20.14	20.04	18.80	8.5	4.1	15.7		
Capital increase	20.08	10.97	0.03	0.3	0.3	0.3		
P/E (x)	62.1	-12.7	-51.1	-18.6	-30.9	23.6		
EV/sales (x)	3.7	3.3	2.5	2.3	2.1	1.8		

Allergy Therapeutics


hardmanoco




R&D investment



Free cashflow



Net cash/(debt) and capital increases



- AGY has a solid existing portfolio of products for allergy immunotherapy
- Products have shown consistent growth over the last five years, even though their availability is limited
- After taking account of manufacturing, distribution and marketing costs, in-market products are profitable
- Product margins have risen consistently over the last five years, reaching 31.9% in fiscal 2017
- Cumulative investment in R&D since 2000 has been £105m
- R&D investment is forecast to rise substantially to get Pollinex Quattro onto the market in the US and formally approved in Europe
- Three key trials for the US and Europe will cost ca.£35m over the next two years, but will pave the way to regulatory approvals in a changing market place
- In each of the last four years, AGY has generated free cashflow from operations
- Considerable investment in R&D and marketing will result in two years' of cash burn
- Cash requirement towards the end of this decade will be dependent on the commercialisation strategy in the US
- In following the inorganic growth strategy, although acquisitions tend to be small, more cash could be required
- £20m was raised in March 2015 largely to fund the key US trials
- Based on current forecasts, the net cash position will reach a neutral position at the end of fiscal 2019
- Should management decide to commercialise Pollinex Quattro in the US by itself, AGY will require working capital for investment in sales infrastructure

Source: Company data; Hardman & Co Life Sciences Research

2018 trading update

Allergy Therapeutics has released a trading update to the market covering the first half of fiscal 2018, which includes headline sales information, the net cash position, and some up-to-date information regarding clinical trial progress. The complete interim statement will be published on 7th March 2018.

Key headlines


- ▶ Underlying sales growth was 1.3% to £42.2m (£40.4m)
- Cash balance was £25.8m at 31st December 2017 vs. £27.8m at 30th June 2017
- Progress with Pollinex Quattro trials in both Europe and the US
- ▶ The PQ Birch Phase III trial is fully recruited results are due in 2H calendar 2018

AGY 1H'18 – actual vs expectations								
Half-year	1H'17	1H'18	CER	1H'18	Delta			
(£m)	actual	actual	growth (%)	forecast	Δ			
Group sales	40.4	42.2	+1.3%	46.4	-4.2			
Cash balance	27.8	25.8	NM	26.2	-0.4			
Net cash/(debt) est.	23.3	22.5	NM	23.0	-0.5			

Source: Allergy Therapeutics; Hardman & Co Life Sciences Research

Sales

Because of the seasonality of the pollen season, AGY sales are traditionally stronger in the first half of each financial year. Having seen consistent double-digit underlying growth at the interim stage for each of the last five years, the outcome in 1H'18 was quite a surprise, with underlying growth of just 1.3%. AGY being first to report financial information for this period, it is difficult to know how this compares with its immediate competitors. However, there are reports that the pollen season in Central Europe – notably key markets in Germany, Austria and Switzerland¹ – was very weak in 2017, which is corroborated by weak sales of OTC allergy products (down 10% in Germany, 2017 data from QuintilesIMS).



¹<u>http://www.meteosuisse.admin.ch/content/dam/meteoswiss/fr/service-und-</u>publikationen/publikationen/doc/bulletin climato saison fruehling-2017 f.pdf

Clinical trial update

PQ Birch

PQ Birch is an ultra-short course convenient-to-use, aluminium-free subcutaneous immunotherapy (SCIT). Around 6% of the EU population is allergic to birch pollen, and European marketing authorisation via the Therapieallergene-Verordnung (TAV) for PQ Birch would represent the first MPL-adjuvant vaccine to be formally licensed, strengthening the position of AGY significantly.

Recruitment into the pivotal PQB301 Phase III study, which is designed to evaluate the safety and efficacy of PQ Birch, is now fully recruited. 560 patients from 59 centres in four European countries have been immunised and will be assessed during the 2018 birch pollen season to measure allergy rhinoconjunctivitis symptoms. Results are due to be released in the second half of calendar 2018.

PQ Grass

Recruitment into the Phase II PQ Grass trial is continuing. Again, data are expected to be released in 2H calendar 2018. Following these results, meetings will be held with both US and German regulators to generate an acceptable Phase III trial design.

OralVac Oral

Plans are on track with the German TAV for the clinical development programme for an oral version of AGY's OralVac vaccine, which a co-development programme recently announced with Ergomed (ERGO.L). A sub-lingual formulation offers an alternative option for patients who prefer not to have injections. Under the terms of the agreement, the clinical development of OralVac products for the treatment of grass pollen, tree pollen, and house dust mite allergies will be progressed by Ergomed. The collaboration includes a future revenue share and reduced service fee.

Changes to forecasts

At this stage, it is very difficult to predict the likely outcome for the pollen season in 2018. However, given the relative weakness observed in 1H'18, it seems prudent to adjust sales forecasts to a more conservative growth rate. Therefore, sales have been reduced by 6% for 2018, which has a knock-on effect on future years. Readers are reminded that, at this stage of the year, all forecasts are based on constant currency to provide a true picture of growth expectations.

In addition, timing of R&D spend is difficult to predict. Therefore, R&D investment has been maintained for the full-year at -£18.0m, suggesting an even more significant 2H bias than previously forecast. With tight cost control, the impact on pre-tax profit of these changes is only about £0.5m p.a.

Changes to forecasts				
Year-end June (£m)	2017	2018E	2019E	2020E
Group sales				
Old	64.1	72.0	81.5	92.0
New	-	68.0	77.0	86.5
Change		-6%	-6%	-6%
Pre-tax profit				
Old	-3.0	-9.3	-5.5	8.5
New	-	-9.8	-6.0	8.0
Change		-5%	-10%	-6%
EPS (p)	-0.6	-1.6	-1.0	1.3

Financial forecasts

Profit & Loss

- ► Sales: Underlying sales growth for 2018 has been reduced from 13% to 6%, reflecting the weaker-than-expected pollen season in the first half.
- R&D: The investment is being maintained at -£18.0m for 2018, suggesting a much greater 2H bias than previously forecast.
- ▶ Forex: Even though there was a small currency benefit in 1H'18, it seems prudent to keep forecasts on a constant currency basis given recent signs of sterling strengthening. Readers are reminded that AGY has a natural currency hedge, with most of the marketing and R&D costs also being in EUR.

Profit & Loss account						
Year-end June (£m)	2015	2016	2017	2018E	2019E	2020E
GBP:EUR	1.270	1.338	1.171	1.171	1.171	1.171
GBP:USD	1.576	1.484	1.281	1.281	1.281	1.281
Sales	43.23	48.51	64.14	68.01	77.04	86.49
COGS	-12.18	-14.07	-16.77	-17.51	-19.53	-17.08
Gross profit	31.05	34.44	47.37	50.50	57.51	69.41
Marketing	-17.06	-20.22	-26.89	-27.90	-32.14	-36.95
Product profit	13.99	14.22	20.48	22.60	25.37	32.46
Product margin	32.4%	29.3%	31.9%	33.2%	32.9%	37.5%
G&A	-8.03	-10.33	-14.08	-14.28	-15.25	-16.35
R&D	-3.12	-16.22	-9.30	-18.00	-16.00	-8.00
EBITDA	4.20	-10.68	-1.24	-8.02	-3.94	10.05
Depreciation	-1.01	-1.39	-1.66	-1.66	-1.94	-1.94
Other income	0.07	0.00	0.00	0.00	0.00	0.00
Underlying EBIT	2.91	-12.34	-2.89	-9.68	-5.88	8.11
Share-based costs	-0.41	-0.33	-0.70	-0.70	-0.70	-0.70
Exceptional items	-1.10	0.14	1.00	0.00	0.00	0.00
Statutory EBIT	1.41	-12.53	-2.60	-10.38	-6.58	7.41
Net financials	-0.07	-0.11	-0.07	-0.13	-0.13	-0.11
Pre-tax profit	2.84	-12.45	-2.97	-9.80	-6.00	8.00
Extraordinary items	-0.68	0.43	0.00	0.00	0.00	0.00
Reported pre-tax	0.65	-12.21	-2.67	-10.51	-6.71	7.30
Tax payable/credit	-0.55	-0.86	0.19	0.21	0.23	-0.44
Minorities	0.00	0.00	0.00	0.00	0.00	0.00
Underlying net income	2.29	-13.46	-3.48	-9.60	-5.78	7.56
Statutory net income	0.11	-13.07	-2.48	-10.30	-6.48	6.86
Ordinary 0.1p shares:						
Period-end (m)	545.8	589.2	594.1	594.1	594.1	594.1
Weighted average (m)	475.2	570.3	592.2	594.1	594.1	594.1
Fully diluted (m)	498.2	589.2	615.1	622.0	627.0	635.0
Underlying basic EPS (p)	0.48	-2.36	-0.59	-1.62	-0.97	1.27
Statutory basic EPS (p)	0.02	-2.29	-0.42	-1.73	-1.09	1.15
U/l fully-diluted EPS (p)	0.46	-2.28	-0.57	-1.54	-0.92	1.19
Stat. fully-diluted EPS (p)	0.02	-2.22	-0.40	-1.66	-1.03	1.08
DPS (p)	0.00	0.00	0.00	0.00	0.00	0.00
			Source: Ho	ardman & Co	Life Science	s Research

Balance sheet

Net cash/(debt): At 31st December 2017, AGY had a cash balance of £25.8m, which we estimate to equate to a net cash of £22.5m, a rise of £3.5m compared with the position at the end of June 2017. Cash will outflow in 2H'18, leaving net cash at ca.£8.5m at the end of June 2018.

Balance sheet						
@30th June (£m)	2015	2016	2017	2018E	2019E	2020E
Shareholders' funds	34.47	30.32	29.97	19.67	13.19	20.04
Cumulated goodwill	0.00	0.00	0.00	0.00	0.00	0.00
Total equity	34.47	30.32	29.97	19.67	13.19	20.04
Share capital	0.56	0.60	0.60	0.60	0.60	0.60
Reserves	33.91	29.73	29.36	19.06	12.58	19.44
Capitalised R&D	9.43	21.13	25.42	36.43	43.65	42.13
Minorities	0.00	0.00	0.00	0.00	0.00	0.00
Provisions/liabilities	0.21	1.44	0.70	0.70	0.70	0.70
Deferred tax	0.30	0.33	0.35	0.35	0.35	0.35
Long-term loans	1.55	3.07	2.94	2.94	2.94	2.94
Short-term loans	0.30	0.30	0.39	5.39	15.39	3.83
<i>less:</i> Cash	21.20	23.41	22.12	16.84	22.42	22.42
<i>less:</i> Deposits	0.78	0.00	0.00	0.00	0.00	0.00
less: Non-core invests.	3.16	4.05	4.59	4.59	4.59	4.59
Invested capital	27.86	39.32	42.66	53.66	58.82	52.59
Fixed assets	8.75	9.67	9.67	9.82	10.23	11.68
Intangible assets	2.02	2.08	2.07	1.79	1.51	1.23
Capitalised R&D	9.43	21.13	25.42	36.43	43.65	42.13
Goodwill	2.98	3.27	3.39	3.39	3.39	3.39
Inventories	6.75	7.69	7.48	7.44	8.42	9.46
Trade debtors	2.84	4.68	4.19	4.44	6.57	8.95
Other debtors	2.22	1.84	3.67	3.67	3.67	3.67
Tax liability/credit	-0.59	-1.43	-1.43	-1.43	-1.43	-1.43
Trade creditors	-3.05	-3.11	-4.11	-4.36	-9.22	-17.29
Other creditors	-3.53	-6.51	-7.68	-7.52	-7.97	-9.19
Debtors less creditors	-2.11	-4.53	-5.37	-5.20	-8.39	-15.30
Invested capital	27.81	39.32	42.66	53.66	58.82	52.59
Net cash/(debt)	20.14	20.04	18.80	8.5	4.1	15.7
Net debt/equity (%)	58%	66%	63%	43%	31%	78%
After-tax ROIC	9%	-33%	-8%	-17%	-9%	15%
NAV/share (p)	7.25	5.32	5.06	3.31	2.22	3.37
Stock days	198	182	165	148	151	181
Debtor days	24	28	25	23	26	33
Creditor days	83	80	79	88	127	283

Cashflow

- 1H'18 inflow: From the trading side there is a natural bias to the first half of the year because of the seasonality of business. Product sales are profitable and cash-generative. In the absence of large R&D investment during the period, this drops all the way through the accounts.
- R&D investment: Coupled to this, R&D investment in fiscal 2018 is expected to be biased to the second half of the year.
- Net debt: Consequently, there was an estimated cash generation of £3.7m in the first half. The lower level of trading seen in the second half, coupled with increased R&D spend, will lead to a significant cash outflow, with net cash estimated at ca.£8.5m on 30th June 2018.

Cashflow						
Year-end June (£m)	2015	2016	2017	2018E	2019 E	2020E
Underlying EBIT	2.91	-12.34	-2.89	-9.68	-5.88	8.11
Depreciation	1.01	1.39	1.66	1.66	1.66	1.66
Amortisation	0.28	0.28	0.28	0.28	0.28	0.28
Inventories	-0.42	-0.59	0.33	0.05	-0.99	-1.03
Receivables	-0.45	-0.37	1.00	-0.25	-6.57	-2.38
Payables	1.08	-0.50	0.82	0.25	9.22	8.07
Change in working capital	0.21	-1.45	2.16	0.04	1.67	4.66
Exceptionals/provisions	0.29	0.00	0.00	0.00	0.00	0.00
Disposals	0.00	0.00	0.00	0.00	0.00	0.00
Other	-0.98	-0.15	0.11	0.00	0.00	0.00
Company op. cashflow	3.72	-12.28	1.32	-7.70	-2.28	14.70
Net interest	-0.24	-0.39	-0.18	-0.13	-0.13	-0.11
Tax paid/received	-0.17	0.09	-1.10	-0.51	0.21	0.23
Operational cashflow	3.31	-12.57	0.03	-8.33	-2.20	14.82
Capital expenditure	-1.09	-1.23	-1.50	-1.80	-2.07	-3.11
Capitalised R&D	0.00	0.00	0.00	0.00	0.00	0.00
Sale of fixed assets	0.00	0.00	0.00	0.00	0.00	0.00
Free cashflow	2.22	-13.80	-1.47	-10.13	-4.27	11.71
Dividends	0.00	0.00	0.00	0.00	0.00	0.00
Acquisitions	-2.67	0.00	-0.23	-0.10	-0.10	-0.10
Disposals	0.00	0.00	0.00	0.00	0.00	0.00
Other investments	-0.28	-0.26	-0.26	-0.30	-0.30	-0.30
CF after investments	-0.72	-14.06	-1.95	-10.53	-4.67	11.31
Share repurchases	0.00	0.00	0.00	0.00	0.00	0.00
Share issues	20.08	10.97	0.03	0.25	0.25	0.25
Currency effect	-1.10	3.00	0.67	0.00	0.00	0.00
Borrowings acquired	-0.37	0.00	0.00	0.00	0.00	0.00
Change in net debt	17.88	-0.10	-1.25	-10.28	-4.42	11.56
Opening net cash	2.20	20.14	20.04	10.70	0.54	4.00
Closing net cash	2.26	20.14	20.04	18.79	8.51	4.09
-	20.14	20.04	18.79	8.51	4.09	15.66
Hardman FCF/share (p)	0.70	-2.20	0.01	-1.40	-0.37	2.49

Allergy Therapeutics



Disclaimer

Hardman & Co provides professional independent research services. Whilst every reasonable effort has been made to ensure that the information in the research is correct, this cannot be guaranteed.

The research reflects the objective views of the analysts named on the front page. However, the companies or funds covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. A full list of companies or funds that have paid us for coverage within the past 12 months can be viewed at http://www.hardmanandco.com/

Hardman & Co has a personal dealing policy which debars staff and consultants from dealing in shares, bonds or other related instruments of companies which pay Hardman for any services, including research. They may be allowed to hold such securities if they were owned prior to joining Hardman or if they were held before the company appointed Hardman. In such cases sales will only be allowed in limited circumstances, generally in the two weeks following publication of figures.

Hardman & Co does not buy or sell shares, either for its own account or for other parties and neither does it undertake investment business. We may provide investment banking services to corporate clients.

Hardman & Co does not make recommendations. Accordingly, we do not publish records of our past recommendations. Where a Fair Value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities/companies but has no scheduled commitment and may cease to follow these securities/companies without notice.

Nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell securities by us.

This information is not tailored to your individual situation and the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial adviser.

This report may not be reproduced in whole or in part without prior permission from Hardman &Co.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259. However, the information in this research report is not FCA regulated because it does not constitute investment advice (as defined in the Financial Services and Markets Act 2000) and is provided for general information only.

Hardman & Co Research Limited (trading as Hardman & Co) 35 New Broad Street London EC2M 1NH +44 (0) 20 7194 7622 Follow us on Twitter @HardmanandCo

(Disclaimer Version 4 – Effective from January 2018)

Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman research and, specifically, whether it can be accepted without a commercial arrangement. Hardman's company research is paid for by the companies about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are' (b) 'written material from a third party that is commissioned and paid for by an[sic] corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public;'

The fact that we are commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <u>http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-</u>2031.pdf

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman is not inducing the reader of our research to trade through us, since we do not deal in any security.

Hardman & Co

35 New Broad Street London EC2M 1NH

Tel: +44(0)20 7194 7622

www.hardmanandco.com

